NASDAQ:DMAC

Diamedica Therapeutics Stock Forecast

etoro logo Buy DMAC
*Your capital is at risk
$7.67
-0.0400 (-0.519%)
At Close: Jul 10, 2026
AI Analysis AI Analysis of DMAC AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add DMAC to Watchlist?
Some Reasons Why To Add DMAC:
  • +111.3% price growth over the last year
  • Low bankruptcy risk (Altman Z-Score: 36.70)
  • Bullish trend confirmed on both short and long timeframes
PDF

Red day on Friday for DiaMedica Therapeutics Inc.
(Updated on Jul 10, 2026)

Buy or Hold candidate since Jun 24, 2026 Gain 20.60%

The DiaMedica Therapeutics Inc. stock price fell by -0.519% on the last day (Friday, 10th Jul 2026) from $7.71 to $7.67. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 9.17% from a day low at $7.31 to a day high of $7.98. The price has been going up and down for this period, and there has been a 24.72% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -24 thousand shares and in total, 163 thousand shares were bought and sold for approximately $1.25 million.

The stock lies in the upper part of a very wide and weak rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $8.05 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 8.13% during the next 3 months and, with a 90% probability hold a price between $5.98 and $8.70 at the end of this 3-month period.

DMAC Signals & Forecast

The DiaMedica Therapeutics Inc. stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $7.77. On a fall, the stock will find some support from the long-term average at approximately $6.31. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Monday, July 06, 2026, and so far it has fallen -4.24%. Further fall is indicated until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for DiaMedica Therapeutics Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $7.22 and $6.55. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, DiaMedica Therapeutics Inc. finds support just below today's level at $7.22. If this is broken, then the next support from accumulated volume will be at $6.55 and $6.32.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved $0.670 between high and low, or 9.17%. For the last week the stock has had daily average volatility of 6.84%.

The DiaMedica Therapeutics Inc. stock is overbought on RSI14 and the RSI has been falling for the last couple of days. This together with the fact that the stock is in the upper part of the trend poses a possible good selling opportunity for the short-term trader. However, one should note that some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.

Our recommended stop-loss: $7.30 (-4.80%) (This stock has very high daily movements and this gives very high risk. The RSI14 is 78 and this increases the risk substantially. There is a sell signal from a pivot top found 4 days ago.)

Trading Expectations (DMAC) For The Upcoming Trading Day Of Monday 13th

For the upcoming trading day on Monday, 13th we expect DiaMedica Therapeutics Inc. to open at $7.65, and during the day (based on 14 day Average True Range), to move between $7.44 and $7.90, which gives a possible trading interval of +/-$0.458 (+/-6.16%) up or down from last closing price. If DiaMedica Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 6.16% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $7.96 (3.78%) than the support at $7.22 (5.87%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is DiaMedica Therapeutics Inc. stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for DiaMedica Therapeutics Inc. stock to perform well in the short-term.

Current score: 1.122 Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on July 13, 2026 - $7.65 ( 0.217%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

DMAC Performance

Trading levels for DMAC

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 8.32 8.52%
R2 8.07 5.18%
R1 7.91 3.12%
Price 7.67
S1 7.40 -3.55%
S2 7.24 -5.62%
S3 6.98 -8.95%

Accumulated Volume Support & Resistance Levels

Level Price
R3 8.01 4.43%
R2 7.99 4.17%
R1 7.96 3.78%
Price 7.67
S1 7.22 -5.87%
S2 6.55 -14.60%
S3 6.32 -17.60%

FAQ

What is the symbol for DiaMedica Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for DiaMedica Therapeutics Inc. is DMAC and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell DiaMedica Therapeutics Inc. Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for DiaMedica Therapeutics Inc. stock to perform well in the short-term.

How to buy DiaMedica Therapeutics Inc. Stock?
DiaMedica Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy DiaMedica Therapeutics Inc. Stock.

What's the current price of DiaMedica Therapeutics Inc. Stock?
As of the end of day on the Jul 10, 2026, the price of an DiaMedica Therapeutics Inc. (DMAC) share was $7.67.

What is the 52-week high and low for DiaMedica Therapeutics Inc. Stock?
The 52-week high for DiaMedica Therapeutics Inc. Stock is $10.42 and the 52-week low is $3.58.

What is the market capitalization of DiaMedica Therapeutics Inc. Stock?
As of the Jul 10, 2026, the market capitalization of DiaMedica Therapeutics Inc. is 413.285M.

When is the next earnings date for DiaMedica Therapeutics Inc.?
The upcoming earnings date for DiaMedica Therapeutics Inc. is Aug 11, 2026.
Click to get the best stock tips daily for free!
ABOUT DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
20.56% Jun 29
NMRK
$15.02
2.13% Jun 24
NESR
$25.07
11.21% Jun 23
IDYA
$28.98
28.64% Jun 12
GIB
$66.69
0.300% Jun 12

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE